Skip to content
Radiation Lab
Sr-89 half-life, beta range, bremsstrahlung

Strontium-89

Sr-89 · Strontium, Z = 38, A = 89

At 1.07e+15 Bq/g — 2.90e+4 Ci/g — a gigabecquerel of Sr-89 amounts to 930 ng, which is why activity rather than mass is how anyone states the quantity. Strontium-89 decays by beta-minus emission with a half-life of 50.563 days, falling to 66.28% of today's activity in a month and 0.67% in a year.

The air kerma rate constant is small — 0.0000113 mGy·m²/(GBq·h), 6,800× less than Cs-137 and 27,000× less than Co-60, ranking 89 of 96 by Γ — near the bottom of the photon emitters, but above the cutoff, which 51 nuclides in this dataset are not. It takes 1.77 TBq at a metre to reach 20 µSv/h from the photons alone.

One line at 909.0 keV carries the whole of the dose rate.

At 1 GBq and a metre the dose rate from Sr-89's own photons is already under 20 µSv/h with nothing in the way; where a larger source does need a shield for this line, it is a thick one — 7.82 mm of lead for a factor of two and 26.0 mm for a factor of ten, or 14.0 mm of steel for a factor of two.

The beta endpoint is 1.50 MeV, mean 0.587 MeV over 2 branches. That endpoint stops in 5.70 mm of acrylic or 2.71 mm of glass. Of the beta energy, 0.34% turns into X-rays in acrylic and 4.31% in lead.

Sr-89 skeletal retention and separation from radiostrontium mixtures

Sr-89 delivers beta radiation to sites of bone formation and is used as strontium chloride to relieve pain from skeletal metastases. Its calcium-like chemistry promotes incorporation into bone mineral, with preferential uptake where osteogenesis is active. The chloride is retained longer in metastatic lesions than in normal bone, concentrating irradiation near those sites. This is a treatment for metastatic bone pain, rather than a general treatment for cancer in tissues that do not involve bone. The product information describes a delayed onset of pain relief after injection.

Skeletal localisation does not remove the possibility of marrow toxicity. The product information describes suppression of white cells and platelets, with blood-count monitoring relevant to treatment and any later administration. Excretion also matters: activity leaves mainly through urine, and renal dysfunction can affect the balance of benefit and risk. These clinical features arise from where the strontium goes and how long it remains there. They cannot be inferred simply from the very small external photon output or from a statement that the isotope is predominantly a beta emitter.

In a radiochemical laboratory, Sr-89 presents another problem because chemical separation collects it together with Sr-90. The EPA method for contaminated building materials first isolates strontium from the matrix and potential interferents, then measures beta emission with a gas-flow proportional counter. That initial result is a total radiostrontium measurement, not an automatic identification of the isotope present. Recounting the prepared sample permits the changing contribution of Sr-89 and the ingrowth of Y-90 from Sr-90 to be included in the analysis.

The daughter distinction provides the physical basis for that separation in time. Sr-89 decays mainly into stable Y-89, whereas the Sr-90 contribution develops an additional beta signal from Y-90. The EPA method also discusses faster Cherenkov measurements when appreciable Sr-89 is suspected, with a higher detection limit than proportional counting. Unremoved alpha emitters can bias a beta result through detector cross-talk, so radiochemical purity and counting behaviour both matter. A clean-looking strontium fraction is not enough to establish isotope-specific activity; the measurement sequence and the treatment of interfering signals determine what the reported result actually represents.

Half-life, specific activity, dose rate and beta energies

Half-life50.563 days (4.369e+6 s)
Decay modebeta-minus decay
Specific activity1.07e+15 Bq/g (2.90e+4 Ci/g)
Air kerma rate constant Γ (δ = 20 keV)0.0000113 mGy·m²/(GBq·h)
Dose rate, 1 GBq at 1 m0.0000113 mGy/h
Dose rate, 1 Ci at 1 m0.000417 mGy/h
Kerma-weighted mean photon energy909.0 keV
Beta endpoint / mean1.50 MeV / 0.587 MeV

A single photon line at 909 keV

No recorded line for Sr-89 falls below the 20 keV cutoff, so this table is the whole photon spectrum. Probability and dose share.

Energy (keV)Emission probability (%)Share of dose rate (%)
908.960.00956100.00

7.82 mm of lead halves this spectrum

Solved for the single line, narrow beam. How the half-value layer is solved.

MaterialHVL (mm)TVL (mm)TVL / HVL
lead7.8226.03.32
tungsten4.9916.63.32
iron14.046.53.32
copper12.541.53.32
concrete44.31473.32
water93.73113.32
aluminum39.91333.32

With one line the ratio is the single-energy 3.32. Spectrum and attenuation ratios.

5.70 mm of acrylic stops the 1.50 MeV endpoint

Katz–Penfold fit to the 1.50 MeV endpoint — a stopping thickness rather than an attenuation length. Why the material matters more than the thickness.

AbsorberRange for the endpoint (mm)
acrylic5.70
aluminum2.51
water6.78
glass2.71
Shield materialFraction of beta energy converted to X-rays
acrylic (Z ≈ 6.5)0.34%
lead (Z = 82)4.31%

Activity over months and years

Ten half-lives is 1.38 years — for Sr-89 itself, a storage problem rather than a disposal one, with 0.67% of today's activity still there after a year. The mean life 1/λ is 72.9 days.

ElapsedFraction remaining
1 half-life50.0 %
2 half-lives25.0 %
5 half-lives3.13 %
10 half-lives0.0977 %
Time to fall to 10 % of today's activity168 days
Time to fall to 1 %336 days
Time to fall to 0.1 %1.38 years

Limits of these dose rates

Gamma, beta and decay calculators for Sr-89

Other Strontium nuclides: Sr-85, Sr-85m, Sr-90

Computed from the IAEA Nuclear Data Section — Livechart API (ENSDF) and the NIST X-Ray Mass Attenuation Coefficients. Derivations and citations.